benzofurans and Acinetobacter-Infections

Acinetobacter baumannii is an opportunistic Gram-negative bacterial pathogen, associated mostly with hospital-acquired infections. The emergence of drug resistance strains made it necessary to explore new pathways for the development of more effective antibiotics. Enoyl CoA reductase (FabI), a key enzyme in the fatty acid biosynthesis (FAS) pathway, has emerged as a potential target for antibacterial drug development. Earlier reports show that the lead SaFabI inhibitor AFN-1252 can inhibit FabI from other organisms including Escherichia coli and Burkholderia pseudomallei, but with differential potency. In the present work, we show that AFN-1252 is a moderate inhibitor of AbFabI with an IC

Topics: Acinetobacter baumannii; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Benzofurans; Burkholderia pseudomallei; Crystallization; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Escherichia coli; Fatty Acid Desaturases; Humans; NAD; Pyrones; Transition Temperature